Scientists believe a pharmaceutical version of a naturally occurring peptide could protect lungs from coronavirus

Coronavirus lung scan.
(Image credit: KENZO TRIBOUILLARD/AFP via Getty Images)

While the pharmaceutical industry has mainly focused on developing antiviral drugs that can fight off coronavirus infections and vaccines, one biotech firm is working on a treatment that would protect a patient's lungs from COVID-19's worst effects, Stat News reports.

Scientists now have a clear sense that the virus enters a person's system through ACE2, an enzyme commonly found on the surface of lung cells. One of ACE2's jobs is to prevent inflammation, but when it's interrupted (as it is in coronavirus patients), it can no longer keep a peptide that constricts blood vessels, known as angiotensin II, in check. Normally, ACE2 would fend off angiotensin II by converting it to angiotensin-(1-7), another peptide that relaxes the vessels and reduces inflammation, protecting people from blood clots and oxidation, which some COVID-19 patients have suffered from.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.